(22UA) BioNTech SE - Overview
Stock: Cancer Vaccines, Immunotherapies, mRNA Therapies, Oncology Pipeline
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 45.5% |
| Relative Tail Risk | -24.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.35 |
| Alpha | -29.09 |
| Character TTM | |
|---|---|
| Beta | 0.359 |
| Beta Downside | 0.269 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.72% |
| CAGR/Max DD | -0.24 |
Description: 22UA BioNTech SE December 19, 2025
BioNTech SE (XETRA: 22UA) is a German biotech firm that leverages its mRNA platform to develop a broad pipeline of cancer immunotherapies. Its current clinical portfolio spans early-stage (Phase 1) to late-stage (Phase 3) trials, including BNT111 for advanced melanoma, BNT311/GEN1046 (acasunlimab) in Phase 3 for solid tumors, and BNT327 targeting multiple indications such as small-cell lung cancer and hepatocellular carcinoma. The company, founded in 2008 and headquartered in Mainz, focuses on both solid-tumor and hematologic indications across a range of trial phases.
Key recent metrics: BioNTech reported €4.9 billion in total revenue for FY 2023, driven largely by its COVID-19 vaccine partnership with Pfizer, while R&D expenditure remained high at ~€1.5 billion, reflecting the capital-intensive nature of mRNA therapeutics. The broader biotech sector is benefitting from accelerated regulatory pathways for cell-based and gene-editing therapies, but also faces pricing pressure from health-care payers in Europe and the U.S. BioNTech’s cash position of roughly €3.2 billion at year-end provides runway for its extensive pipeline, though execution risk remains high for later-stage oncology trials.
For a deeper quantitative assessment of BioNTech’s valuation metrics, you may find the ValueRay platform useful.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -571.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.05 > 0.02 and ΔFCF/TA -9.46 > 1.0 |
| NWC/Revenue: 431.7% < 20% (prev 525.1%; Δ -93.44% < -1%) |
| CFO/TA -0.05 > 3% & CFO -1.06b > Net Income -571.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (240.5m) vs 12m ago 0.30% < -2% |
| Gross Margin: 85.62% > 18% (prev 0.87%; Δ 8475 % > 0.5%) |
| Asset Turnover: 14.41% > 50% (prev 13.57%; Δ 0.84% > 0%) |
| Interest Coverage Ratio: -28.29 > 6 (EBITDA TTM -550.1m / Interest Expense TTM 33.0m) |
Altman Z'' 10.00
| A: 0.64 (Total Current Assets 15.83b - Total Current Liabilities 2.22b) / Total Assets 21.34b |
| B: 0.85 (Retained Earnings 18.24b / Total Assets 21.34b) |
| C: -0.04 (EBIT TTM -933.5m / Avg Total Assets 21.87b) |
| D: 6.45 (Book Value of Equity 18.49b / Total Liabilities 2.86b) |
| Altman-Z'' Score: 13.46 = AAA |
Beneish M -2.86
| DSRI: 0.68 (Receivables 699.7m/988.0m, Revenue 3.15b/3.04b) |
| GMI: 1.01 (GM 85.62% / 86.53%) |
| AQI: 1.63 (AQ_t 0.20 / AQ_t-1 0.12) |
| SGI: 1.04 (Revenue 3.15b / 3.04b) |
| TATA: 0.02 (NI -571.6m - CFO -1.06b) / TA 21.34b) |
| Beneish M-Score: -2.86 (Cap -4..+1) = A |
What is the price of 22UA shares?
Over the past week, the price has changed by -3.21%, over one month by +5.73%, over three months by -0.77% and over the past year by -20.07%.
Is 22UA a buy, sell or hold?
What are the forecasts/targets for the 22UA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 84.1 | -7% |
22UA Fundamental Data Overview February 03, 2026
P/E Forward = 7.1429
P/S = 7.709
P/B = 1.3316
P/EG = 0.0464
Revenue TTM = 3.15b EUR
EBIT TTM = -933.5m EUR
EBITDA TTM = -550.1m EUR
Long Term Debt = 192.0m EUR (from longTermDebt, last quarter)
Short Term Debt = 53.4m EUR (from shortLongTermDebt, last quarter)
Debt = 245.4m EUR (Calculated: Short Term 53.4m + Long Term 192.0m)
Net Debt = -14.28b EUR (calculated as Total Debt 245.4m - CCE 14.53b)
Enterprise Value = 10.02b EUR (24.30b + Debt 245.4m - CCE 14.53b)
Interest Coverage Ratio = -28.29 (Ebit TTM -933.5m / Interest Expense TTM 33.0m)
EV/FCF = -9.15x (Enterprise Value 10.02b / FCF TTM -1.09b)
FCF Yield = -10.93% (FCF TTM -1.09b / Enterprise Value 10.02b)
FCF Margin = -34.73% (FCF TTM -1.09b / Revenue TTM 3.15b)
Net Margin = -18.13% (Net Income TTM -571.6m / Revenue TTM 3.15b)
Gross Margin = 85.62% ((Revenue TTM 3.15b - Cost of Revenue TTM 453.4m) / Revenue TTM)
Gross Margin QoQ = 91.01% (prev 80.90%)
Tobins Q-Ratio = 0.47 (Enterprise Value 10.02b / Total Assets 21.34b)
Interest Expense / Debt = 2.57% (Interest Expense 6.30m / Debt 245.4m)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -700.1m (EBIT -933.5m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 7.12 (Total Current Assets 15.83b / Total Current Liabilities 2.22b)
Debt / Equity = 0.01 (Debt 245.4m / totalStockholderEquity, last quarter 18.48b)
Debt / EBITDA = 25.96 (negative EBITDA) (Net Debt -14.28b / EBITDA -550.1m)
Debt / FCF = 13.05 (negative FCF - burning cash) (Net Debt -14.28b / FCF TTM -1.09b)
Total Stockholder Equity = 18.83b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.61% (Net Income -571.6m / Total Assets 21.34b)
RoE = -3.04% (Net Income TTM -571.6m / Total Stockholder Equity 18.83b)
RoCE = -4.91% (EBIT -933.5m / Capital Employed (Equity 18.83b + L.T.Debt 192.0m))
RoIC = -3.67% (negative operating profit) (NOPAT -700.1m / Invested Capital 19.10b)
WACC = 7.19% (E(24.30b)/V(24.55b) * Re(7.24%) + D(245.4m)/V(24.55b) * Rd(2.57%) * (1-Tc(0.25)))
Discount Rate = 7.24% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.57%
Fair Price DCF = unknown (Cash Flow -1.09b)
EPS Correlation: -79.18 | EPS CAGR: -33.26% | SUE: -0.16 | # QB: 0
Revenue Correlation: -59.93 | Revenue CAGR: -29.16% | SUE: N/A | # QB: 0